Download Open UK Clinical Trials

GYNECOLOGIC ONCOLOGY PROTOCOLS
11/01/11
MULTIPLE
GOG -0136: ACQUISITION OF HUMAN GYNECOLOGIC SPECIMENS AND SERUM TO
BE USED IN STUDYING THE CAUSES, DIAGNOSIS, PREVENTION AND
TREATMENT OF CANCER
OVARIAN
GOG -0187: PHASE II STUDY OF PACLITAXEL F OR OVARIAN STROMAL
TUMORS AS SECOND-LINE THERAPY
GOG-0212:
A RANDOMIZED PHASE III TRIAL OF MAINTENANCE CHEMOTHERAPY
COMPARING 12 MONTHLY CYCLES OF SINGLE AGENT PACLITAXEL OR
CT-2103 (IND# 70177) VERSUS NO TREATMENT UNTIL DOCUMENTED
RELAPSE IN WOMEN WITH ADVANCED OVARIAN OR PRIMARY
PERITONEAL CANCER WHO ACHIEVE A COMPLETE CLINICAL
RESPONSE TO PRIMARY PLATINUM/TAXANE CHEMOTHERAPY
GOG-0241:
A GCIG INTERGROUP MULTICENTER PHASE III TRIAL OF OPEN LABEL
CARBOPLATIN AND PACLITAXEL +/- NCI SUPPLIED AGENT:
BEVACIZUMAB COMPARED WITH OXALIPLATIN AND CAPECITABINE
+/- BEVACIZUMAB AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH
MUCINOUS EPITHELIAL OVARIAN OR FALLOPIAN TUBE CANCER
GOG-0252:
A PHASE III CLINICAL TRIAL OF BEVACIZUMAB WITH
IV VERSUS IP CHEMOTHERAPY IN OVARIAN, FALLOPIAN TUBE, AND
PRIMARY PERITONEAL CARCINOMA
GOG-0260:
A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY
PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT
PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY
PERITONEAL CANCER
GOG-0262:
A RANDOMIZED PHASE III TRIAL OF EVERY -3-WEEKS PACLITAXEL
VERSUS DOSE DENSE WEEKLY PACLITAXEL IN COMBINATION WITH
CARBOPLATIN WITH OR WITHOUT CONCURRENT AND CONSOLIDATION
BEVACIZUMAB IN THE TREATMENT OF PRIMARY STAGE III OR IV
EPITHELIAL OVARIAN, PERITONEAL OR FALLOPIAN TUBE CANCER
GOG-0264:
A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN
VS. BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED
ADVANCED STAGE AND RECURRENT CHEMONAIVE STAGE SEX CORDSTROMAL TUMORS OF THE OVARY
GOG-9925:
A PHASE I STUDY OF VTX-2337 (IND #78,416) IN COMBINATION WITH
DOXIL (NSC# 712227) IN PATIENTS WITH RECURRENT OR PERSISTENT
EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL
CANCER
OVA2:
MARKER DISCVERY AND CLINICAL TRIAL TESTI NG FOR OVA2 USING
SERUM FROM WOMEN WITH A DOCUMENTED OVARIAN ADNEXAL
MASS
OVB-2003:
BIOMARKER DISCOVERY IN OVARIAN TUMORS AND OTHER
GYNECOLOGIC CONDITIONS
ENDOMETRIAL
GOG-0086P: A THREE ARM RANDOMIZED PHASE II STUDY OF
PACLITAXEL/CARBOPLATIN/ BEVACIZUMAB ,
PACLITAXEL/CARBOPLATIN/TEMSIROLIMUS AND
IXABEPILONE/CARBOPLATIN/BEVACIZUMAB AS INITIAL THERAPY FOR
MEASURABLE STAGE III OR IVA, STAGE IVB, OR RECURRENT
ENDOMETRIAL CANCER
GOG-0238:
A RANDOMIZED TRIAL OF PELVIC IRRADIATION WITH OR WITHOUT
CONCURRENT WEEKLY CISPLATIN IN PATIENTS WITH PELVIC -ONLY
RECURRENCE OF CARCINOMA OF THE UTERINE CORPUS
GOG-0249:
PHASE III TRIAL OF PELVIC RADIATION THERAPY VERSUS VAGINAL
CUFF BRACHYTHERAPY FOLLOWED BY PACLITAXEL/CARBOPLATIN IN
PATIENTS WITH HIGH -RISK, EARLY STAGE ENDOMETRIAL CANCER
GOG-0258:
A RANDOMIZED PHASE III TRIAL OF CISPLATIN AND TUMOR VOLUME
DIRECTED IRRADIATION FOLLOWED BY CARBOPLATIN AND
PACLITAXEL VS. CARBOPLATIN AND PACLITAXEL FOR OPTIMALLY
DEBULKED, ADVANCED ENDOMETRIAL CARCINOMA
GOG-0261:
A RANDOMIZED PHASE III TRIAL OF PACLITAXEL PLUS CARBOPLATIN
VERSUS IFOSFAMIDE PLUS PACLITAXEL IN CHEMOTHERAPY -NAÏVE
PATIENTS WITH NEWLY DIAGNOSED STAGE I -IV, PERSISTENT OR
RECURRENT CARCINOSARCOMA (MIXED MESODERMAL TUMORS) OF
THE UTERUS OR OVARY
CERVIX
GOG-0240: A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH
AND WITHOUT NCI-SUPPLIED BEVACIZUMAB VERSUS THE
NONPLATINUM DOUBLET, TOPOTECAN PLUS PACLITAXEL, WITH AND
WITHOUT NCI-SUPPLIED BEVACIZUMAB, IN STAGE IVB, RECURRENT OR
PERSISTENT CARCINOMA OF THE CERVIX
GOG-0263:
RANDOMIZED PHASE III CLINICAL TRIAL OF ADJUVANT RADIATION
VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA
CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY
AND PELVIC LYMPHADENECTOMY
Studies Under Construction
11-GYN-130: Treatment of Endometrial Cancer Utilizing Pathology Intraoperative Consultation to
Determine Extent of Surgical Staging (Ueland)
11-GYN-098: Neoadjuvant Platinum-based Chemotherapy in Advanced Ovarian, Fallopian Tube,
and Primary Peritoneal Carcinoma Trial Protocol (Miller)